Plain-English translation of NCT06689254 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether mifepristone—a medication that blocks the body's stress hormone system—can help people with treatment-resistant PTSD (a severe anxiety disorder that develops after traumatic experiences). Right now, some people with PTSD don't get better even after trying standard treatments like therapy or antidepressants. Researchers think this medication might help by reducing how the stress system overreacts in the brain.
Many people with PTSD don't respond well to current treatments, leaving them stuck with severe symptoms like flashbacks, nightmares, and anxiety. New research suggests that PTSD may involve problems with how the body's stress-response system works, so this medication—which targets that system differently—might offer hope for people who've already tried other options without success.
You likely qualify if…
You likely don't qualify if…
If you're accepted into the study, you'll be randomly assigned to either take mifepristone or a placebo (dummy pill) for a few weeks. You'll visit the clinic for baseline assessments and then return at regular intervals—weekly or monthly—so researchers can measure your PTSD symptoms using standardized questionnaires and interviews. The study lasts about 12 weeks total, and you'll be monitored to track whether your symptoms improve and to watch for any side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Netherlands